Abstract
Background and Objective: Stroke is a leading cause of morbidity and mortality in both developed and developing countries all over the world. The only drug for ischemic stroke approved by FDA is recombinant tissue plasminogen activator (rtPA). However, only 2-5% stroke patients receive rtPAs treatment due to its strict therapeutic time window. As ischemic stroke is a complex disease involving multiple mechanisms, medications with multi-targets may be more powerful compared with single-target drugs. Dl-3-n-Butylphthalide (NBP) is a synthetic compound based on l-3-n- Butylphthalide that is isolated from seeds of Apium graveolens. The racemic 3-n-butylphthalide (dl- NBP) was approved by Food and Drug Administration of China for the treatment of ischemic stroke in 2002. A number of clinical studies indicated that NBP not only improved the symptoms of ischemic stroke, but also contributed to the long-term recovery. The potential mechanisms of NBP for ischemic stroke treatment may target different pathophysiological processes, including anti-oxidant, antiinflammation, anti-apoptosis, anti-thrombosis, and protection of mitochondria et al.
Conclusion: In this review, we have summarized the research progress of NBP for the treatment of ischemic stroke during the past two decades.
Keywords: Dl-3-n-butylphthalide, ischemic stroke, cerebral microcirculation, neuroprotection, mitochondria, apoptosis, oxidative stress.
CNS & Neurological Disorders - Drug Targets
Title:Dl-3-n-Butylphthalide (NBP): A Promising Therapeutic Agent for Ischemic Stroke
Volume: 17 Issue: 5
Author(s): Shan Wang, Fei Ma, Longjian Huang, Yong Zhang, Yuchen Peng, Changhong Xing, Yipu Feng, Xiaoliang Wang*Ying Peng*
Affiliation:
- State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050,China
- State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050,China
Keywords: Dl-3-n-butylphthalide, ischemic stroke, cerebral microcirculation, neuroprotection, mitochondria, apoptosis, oxidative stress.
Abstract: Background and Objective: Stroke is a leading cause of morbidity and mortality in both developed and developing countries all over the world. The only drug for ischemic stroke approved by FDA is recombinant tissue plasminogen activator (rtPA). However, only 2-5% stroke patients receive rtPAs treatment due to its strict therapeutic time window. As ischemic stroke is a complex disease involving multiple mechanisms, medications with multi-targets may be more powerful compared with single-target drugs. Dl-3-n-Butylphthalide (NBP) is a synthetic compound based on l-3-n- Butylphthalide that is isolated from seeds of Apium graveolens. The racemic 3-n-butylphthalide (dl- NBP) was approved by Food and Drug Administration of China for the treatment of ischemic stroke in 2002. A number of clinical studies indicated that NBP not only improved the symptoms of ischemic stroke, but also contributed to the long-term recovery. The potential mechanisms of NBP for ischemic stroke treatment may target different pathophysiological processes, including anti-oxidant, antiinflammation, anti-apoptosis, anti-thrombosis, and protection of mitochondria et al.
Conclusion: In this review, we have summarized the research progress of NBP for the treatment of ischemic stroke during the past two decades.
Export Options
About this article
Cite this article as:
Wang Shan, Ma Fei, Huang Longjian, Zhang Yong, Peng Yuchen, Xing Changhong, Feng Yipu, Wang Xiaoliang*, Peng Ying*, Dl-3-n-Butylphthalide (NBP): A Promising Therapeutic Agent for Ischemic Stroke, CNS & Neurological Disorders - Drug Targets 2018; 17 (5) . https://dx.doi.org/10.2174/1871527317666180612125843
DOI https://dx.doi.org/10.2174/1871527317666180612125843 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thrombosis in Paroxysmal Nocturnal Hemoglobinuria at a Glance: A Clinical Review
Current Vascular Pharmacology Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis
Current Pharmaceutical Design Platelet-Derived Chemokines in Atherogenesis: What’s New?
Current Vascular Pharmacology Pleiotropic Effects of ARB in Metabolic Syndrome
Current Vascular Pharmacology PET-MRI Based Molecular Imaging as a Response Marker in Cervical Cancer: A Systematic Review
Current Molecular Imaging (Discontinued) Influences of Maternal Nutritional Status on Vascular Function in the Offspring
Current Drug Targets Preventing Atherosclerosis with Angiotensin-Converting Enzyme Inhibitors: Emphasis on Diabetic Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders A Review on Corrosion Protection of Iron and Steel
Recent Patents on Corrosion Science (Discontinued) Mesenchymal Stem Cells in the Umbilical Cord: Phenotypic Characterization, Secretome and Applications in Central Nervous System Regenerative Medicine
Current Stem Cell Research & Therapy Mechanisms Linking Leptin to Arterial and Venous Thrombosis: Potential Pharmacological Targets
Current Pharmaceutical Design Empyema and Bronchopleural Fistula Following Lung Resection
Current Respiratory Medicine Reviews Diabetes Mellitus, Hypertension and Hypercholesterolemia in Relation to the 10-Year ACS Prognosis; the GREECS Study
Current Vascular Pharmacology Differential Influence of Carotid Stenosis and White Matter Disease on Motor and Cognitive Activation
Current Alzheimer Research Molecular Pathophysiology of Priapism: Emerging Targets
Current Drug Targets Immune Regulation by the Posttranslational Modification O-GlcNAc
Current Signal Transduction Therapy Hypoxia Inducible Factor Stabilization As a Novel Strategy to Treat Anemia
Current Medicinal Chemistry Cellular Uptake Pathways of Nanoparticles: Process of Endocytosis and Factors Affecting their Fate
Current Pharmaceutical Biotechnology Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Protein O-GlcNAcylation: A Critical Regulator of the Cellular Response to Stress
Current Signal Transduction Therapy